MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: Allogeneic HCT

Allogeneic HCT

Latest news

Tag

Hematology-Oncology

Ruxolitinib Improves Failure-Free and Overall Survival Versus Best Available Therapy in Steroid-Refractory Acute GVHD: Final 24‑Month REACH2 Analysis

The 24‑month final analysis of the phase III REACH2 trial shows ruxolitinib produced longer failure‑free survival, improved median overall and event‑free survival, and a longer duration of response versus best available therapy (BAT) in pat

Dec 9, 2025
Hematology-Oncology

Allogeneic HCT in AYA ALL in CR2: MRD-Negativity and Low HCT‑CI Drive Durable Remissions — Dual‑Center Real‑World Outcomes

In 164 adolescents and young adults with ALL transplanted in second remission, 3‑year overall survival was 53% and progression‑free survival 46%. MRD positivity and HCT‑Comorbidity Index >3 predicted worse outcomes; female‑to‑male donor

Nov 15, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story